Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
113.3 USD -8.21% Intraday chart for Sarepta Therapeutics, Inc. -12.23% +17.53%
May. 28 Sarepta Therapeutics Shares Fall After RBC Downgrade MT
May. 28 RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157 MT

Evolution of the average Target Price on Sarepta Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

524.YjN_-SyDb2T6K45SrbDzz2cRUTurO1hwzWyH19ZPZmM.AFlKy0fvCh6Vefcn9NOdng91E0ubVR0quy3lu7V4VA8jQzmvSMAKFapNvg~0b2b99782cc12625c617a7d13ea0b99c

Analyst Recommendations on Sarepta Therapeutics, Inc.

Sarepta Therapeutics Shares Fall After RBC Downgrade MT
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157 MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180 MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $145 From $130, Keeps Buy Rating MT
BMO Capital Starts Sarepta Therapeutics With Outperform Rating, $170 Price Target MT
RBC Trims Price Target on Sarepta Therapeutics to $151 From $155, Keeps Outperform Rating MT
Needham Raises Price Target on Sarepta Therapeutics to $140 From $93, Keeps Buy Rating MT
RBC Raises Price Target on Sarepta Therapeutics to $155 From $148, Keeps Outperform Rating MT
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Buy Rating, $109 Price Target MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors MT
Needham Raises Price Target on Sarepta Therapeutics to $93 From $82, Keeps Buy Rating MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, Cuts Price Target to $40 From $166 MT
Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating MT
Oppenheimer Downgrades Sarepta Therapeutics to Perform From Outperform MT
Needham Adjusts Sarepta Therapeutics Price Target to $82 From $185, Maintains Buy Rating MT
RBC Cuts Price Target on Sarepta Therapeutics to $148 From $217, Keeps Outperform Rating MT
UBS Adjusts Price Target on Sarepta Therapeutics to $174 From $173, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
113.3 USD
Average target price
167.5 USD
Spread / Average Target
+47.77%
High Price Target
224 USD
Spread / Highest target
+97.65%
Low Price Target
128 USD
Spread / Lowest Target
+12.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sarepta Therapeutics, Inc.

RBC Capital Markets
Mizuho Securities
Oppenheimer
UBS
Morgan Stanley
Deutsche Bank Securities
Needham & Co.
BMO Capital
Wedbush
Cantor Fitzgerald
JPMorgan Chase
Goldman Sachs
Citigroup
Evercore ISI
Credit Suisse
TD Cowen
Baird
Berenberg Bank
BTIG
SVB Securities LLC
Guggenheim

Ratings for Sarepta Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. Consensus Sarepta Therapeutics, Inc.